GSK3 impacts the PD1/PD-L1 axis by transcriptional suppression of PD1 expression, leading to the interference of immune escape with similar efficacy as anti-PD1 antibodies, while the inhibition of CXCR4 was effective in restoring T-cell exclusion from the tumor core heterogeneous triple negative breast cancer in PDAC landscapes [4,14]. The gene discussed is CXCR4; the disease is triple-negative breast carcinoma.